Advancing mitochondrial medicine
About Santhera

About


Santhera


We are a Swiss specialty pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.
________

Read more >>

PATIENTS


About mitochondrial diseases


At Santhera, we are passionate about providing treatment options for patients with rare mitochondrial diseases, specifically in the area of neuromuscular and neuro-ophthalmological conditions – diseases that have a severe impact on the lives of affected children and adults.
________

Read more >>
home-picture-01
Our medicines

Health Care Professionals


Our medicines



Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. In September 2015, we received our first European Marketing Authorization for Raxone® in the treatment of patients with Leber’s hereditary optic neuropathy.

________

Read more >>

Investors & Media


Tools and Resources



The Investor and Media center provides information and resources for investor and media communities.

________

Read more >>
Tools and Resources
Working at Santhera

Career


Working @Santhera



Santhera is a dynamic and international employer looking for colleagues who are talented, engaged and committed to growing the organization through the work that they do.

________

Read more >>

Join our Feeds

news

Latest News

September 28, 2016
Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
Read morepdf-icon
Santhera beginnt Phase-III-Studie (SIDEROS) mit Raxone bei Patienten mit Duchenne-Muskeldystrophie und gleichzeitiger Glucocorticoid-Behandlung
Mehr dazupdf-icon


September 13, 2016
Leading medical journal publishes treatment effect of Santhera’s Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
Read morepdf-icon
Führendes medizinisches Fachjournal publiziert Wirksamkeit von Santheras Raxone auf die inspiratorische Atmungsfunktion bei Patienten mit Duchenne-Muskeldystrophie (DMD)
Mehr dazupdf-icon


September 8, 2016
Santhera’s Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia
Read morepdf-icon
Santhera’s Idebenone (Raxone) erhält in Australien Orphan-Drug-Designation für Duchenne-Muskeldystrophie
Mehr dazupdf-icon


September 6, 2016
Santhera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts to Build US Operations and Strengthens Board of Directors
Read morepdf-icon
Santhera veröffentlicht Halbjahresresultate 2016 mit solidem Umsatzwachstum - Das Unternehmen baut Geschäftstätigkeit in den USA auf und verstärkt den Verwaltungsrat
Mehr dazupdf-icon



Earlier press releases can be found here.
To subscribe to our News Feed, please click here.



June 1, 2016


 

June 21, 2016


 

June 21, 2016

facebook

Facebook

linkedin

Linked In

This section of the website is intended to provide healthcare professionals with information about Raxone® and other products in Santhera’s pipeline. I am a healthcare professional I am not a healthcare professional